Nowadays, the HR+/HER2+ subtype has a better prognosis, particularly in metastatic tumours because it has molecular targets for hormone therapy as well as other targeted treatments like Trastuzumab (HerceptinTM) [4]. Here, HR is linked to neoplasm.